Anna Brouwer

25 General introduction, aims and scope 1 16. Rothova A, Ooijman F, Kerkhoff F, Van Der Lelij A, Lokhorst HM. Uveitis masquerade syndromes. Ophthalmology . 2001;108(2):386-399. doi:10.1016/s0161- 6420(00)00499-1 17. Grange LK, Kouchouk A, Dalal MD, et al. Neoplastic masquerade syndromes in patients with uveitis. Am J Ophthalmol . 2014;157(3):526-531. doi:10.1016/j. ajo.2013.11.002 18. Hettinga YM, van Genderen MM, Wieringa W, Ossewaarde-van Norel J, de Boer JH. Retinal Dystrophy in 6 Young Patients Who Presented with Intermediate Uveitis. Ophthalmology . 2016;123(9):2043-2046. doi:10.1016/j.ophtha.2016.03.046 19. Sève P, Cacoub P, Bodaghi B, et al. Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmun Rev . 2017;16(12):1254-1264. doi:10.1016/j.autrev.2017.10.010 20. Richtlijn voor diagnostiek en behandeling van uveitis. Published online 2015. 21. Jabs DA. Epidemiology of uveitis. Ophthalmic Epidemiol . 15(5):283-284. doi:10.1080/09286580802478724 22. Thorne JE, Suhler E, Skup M, et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol . 2016;134(11):1237-1245. doi:10.1001/jamaophthalmol.2016.3229 23. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin . 2005;45(2):1-13. 24. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol . 1990;14(5-6):303-308. doi:10.1007/bf00163549 25. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol . 1996;80(4):332-336. 26. Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm . 2018;26(1):2-16. doi:10.1080/09273948.2016.1196713 27. Ossewaarde-van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory macular edema. Ocul Immunol Inflamm . 2011;19(1):75-83. doi:10.3109/0 9273948.2010.509530 28. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology . 2018;125(5):757-773. doi:10.1016/j. ophtha.2017.11.017 29. Jones NP. The Manchester Uveitis Clinic: The first 3000 patients, 2: Uveitis Manifestations, Complications, Medical and Surgical Management. Ocul Immunol Inflamm . 2015;23(2):127-134. doi:10.3109/09273948.2014.968671 30. Dick AD, Tundia N, Sorg R, et al. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology . 2016;123(3):655-662. doi:10.1016/j.ophtha.2015.10.028 31. Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol (Chicago, Ill 1960) . 2009;127(2):179-186. doi:10.1001/archophthalmol.2008.564